Neurones S.A.
NRO.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.61 | 0.64 | 5.06 | -1.94 |
| FCF Yield | 0.63% | 6.54% | 0.80% | 3.29% |
| EV / EBITDA | 22.42 | 17.53 | 18.92 | 19.73 |
| Quality | ||||
| ROIC | 4.87% | 6.17% | 5.69% | 5.76% |
| Gross Margin | 100.00% | 47.77% | 47.05% | 47.56% |
| Cash Conversion Ratio | 0.60 | 2.66 | 0.62 | 1.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.52% | 14.46% | 13.58% | 12.04% |
| Free Cash Flow Growth | -90.15% | 766.77% | -76.92% | 65.22% |
| Safety | ||||
| Net Debt / EBITDA | -6.57 | -6.37 | -5.36 | -6.20 |
| Interest Coverage | 36.49 | 37.24 | 50.23 | 45.62 |
| Efficiency | ||||
| Inventory Turnover | 64,061.17 | 798.08 | 69.16 | 275.49 |
| Cash Conversion Cycle | 42.63 | 23.31 | 31.96 | 30.18 |